Abstract 3715
Background
The main objective of this project is to develop a mobile application (APP) for monitoring and controlling the management of the therapeutic regime in this group of people, with a view to strengthening communication among patients and health professionals, favoring adherence to therapeutic indications and responding, in a timely manner and in a proactive manner, to the symptoms or complications that may arise associated with the disease, thereby improving the efficacy of the therapy, preventing complications and improving its perception of health and quality of life. In fact, health interventions must transform behavior towards the desired improvement and empowerment of the person, thus facilitating self-management. Its final presentation will be on the form of an APP, which will improve the well-being and quality of life of people with cancer, bringing gains in efficiency and health outcomes, broadening the sense of the adequacy of policies of health. The expected results with the implementation of this APP are: improve and monitor patient adherence to oral and supportive therapies; to prevent, the appearance of complications or symptoms associated with the treatment, through preventive indications of self-care (green alert level); improve patients responses, through self-care uncontrolled complications (yellow alert level); signaling to the patient and health services, uncontrolled symptoms with high severity (red alert level); improve the efficiency of health teams with regard to self-management of the disease and produce and disseminate knowledge in oncology. At this time the project is already at an advanced stage of development. Systematic reviews of the literature were developed to support the interventions included in the APP. The interventions were categorized by the two levels of self-care and were submitted to expert evaluation using the Delphi technique.
Trial design
Systematic reviews of the literature were developed to support the interventions included in the APP. The interventions were categorized by the two levels of self-care and were submitted to expert evaluation using the Delphi technique. The project has already been tested on an initial sample of 40 patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4097 - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Presenter: Stephen V Liu
Session: Poster Display session 3
Resources:
Abstract
1129 - Aspirin and Ticagrelor for the prevention of tumour cell induced platelet aggregation
Presenter: Meera Chauhan
Session: Poster Display session 3
Resources:
Abstract
4514 - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Michele Maio
Session: Poster Display session 3
Resources:
Abstract
5169 - In vitro functional interrogation of viable Circulating Tumor Associated Cells (C-TACs) for evaluating Platin resistance.
Presenter: Stefan Schuster
Session: Poster Display session 3
Resources:
Abstract
5827 - Targeting ARG2 as a novel therapeutic approach for cancer
Presenter: Marcin Grzybowski
Session: Poster Display session 3
Resources:
Abstract
3129 - MPS1 and PLK1 as new therapy targets in TP53 mutated solid tumors
Presenter: Balazs Gyorffy
Session: Poster Display session 3
Resources:
Abstract
2129 - The Tumor Static Exposure (TSE) concept & utility: application to combination treatment of radiation and radiosensitizing agent in tumor xenograft experiments
Presenter: Samer El Bawab
Session: Poster Display session 3
Resources:
Abstract
1814 - General Methodology to Optimize Tumor Treating Fields Delivery Utilizing Numerical Simulations
Presenter: Noa Urman
Session: Poster Display session 3
Resources:
Abstract
3010 - The Australian Exceptional Responders Program: a National collaboration
Presenter: Megan Barnet
Session: Poster Display session 3
Resources:
Abstract
4489 - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies
Presenter: Joaquina Baranda
Session: Poster Display session 3
Resources:
Abstract